Hyperaldosteronism: Difference between revisions
Line 11: | Line 11: | ||
== Classification == | == Classification == | ||
Aldosteronism and mineralocorticoid excess may be classified into two types, primary hyperaldosteronism (conn's syndrome) and secondary hyperaldosteronism. The different types of aldosteronism described in the below table: | Aldosteronism and mineralocorticoid excess may be classified into two types, primary hyperaldosteronism (conn's syndrome) and secondary hyperaldosteronism. The different types of aldosteronism described in the below table: | ||
{| class="wikitable" | {| class="wikitable" | ||
! | !High renin causes | ||
! | !Disease | ||
! | ! | ||
! | ! | ||
! | ! | ||
|- | |- | ||
| | | rowspan="2" |Genetic mutation | ||
| | |Bartter and Gitelman syndromes | ||
|Hyperplasia of the juxtaglomerular apparatus (the source of renin in the kidney), | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |Liddle syndrome or pseudohypoaldosteronism type 1 | ||
| | |due to resistance to the actions of aldosterone | ||
| | | | ||
| | | | ||
|- | |- | ||
| rowspan="4" |Renovascular | |||
|Kidney transplant | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
|Renin-secreting juxtaglomerular cell tumors | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
|Scleroderma renal crisis | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
|Malignant hypertension | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
|Tumors | |||
|Reninoma | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
|Intravascular hypovolemia | |||
|heart failure, hepatic cirrhosis, and nephrotic syndrome | |||
| | |||
| | |||
| | | | ||
| | |} | ||
{| class="wikitable" | |||
! rowspan="2" |Classification | |||
! rowspan="2" |Disease | |||
! rowspan="2" |Cause | |||
! colspan="4" |Laboratory | |||
|- | |||
!Renin activity | |||
!Aldosterone levels | |||
!urinary free cortisone | |||
! | |||
|- | |||
| rowspan="4" |Secondary hyperaldosteronism | |||
|[[Renin-producing tumors]] | |||
| | | | ||
|↑ | |↑ | ||
Line 87: | Line 85: | ||
| | | | ||
|- | |- | ||
|Renal artery stenosis | |||
| | |||
| | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
|Cushing syndrome | |||
| | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |Ectopic ACTH production | ||
| | | | ||
|↓ | |↓ | ||
| | |↑ | ||
| | |Markedly ↑↑ | ||
| | | | ||
|- | |- | ||
| | | rowspan="2" |Primary hyperaldosteronism | ||
| | |Primary hyperaldosteronism | ||
| | | | ||
|↓ | |↓ | ||
| | |↑ | ||
|↓ | |↓ | ||
| | | | ||
|- | |- | ||
|Familial hyperaldosteronism | |||
| | | | ||
| | |↓ | ||
|↑ | |||
| | |||
|↓ | |↓ | ||
| | | | ||
Line 135: | Line 129: | ||
! rowspan="2" |Cause | ! rowspan="2" |Cause | ||
! | ! | ||
! colspan=" | ! colspan="4" |Labratory | ||
! | ! | ||
|- | |- | ||
Line 142: | Line 136: | ||
!Renin | !Renin | ||
!Aldosterone | !Aldosterone | ||
!Other | |||
!Treatment | !Treatment | ||
|- | |- | ||
Line 151: | Line 146: | ||
| rowspan="2" |↓ | | rowspan="2" |↓ | ||
| rowspan="2" |↓ | | rowspan="2" |↓ | ||
| | |||
| rowspan="2" | | | rowspan="2" | | ||
|- | |- | ||
|11b-hydroxylase | |11b-hydroxylase | ||
| | |||
| | | | ||
| | | | ||
Line 163: | Line 160: | ||
|↓ | |↓ | ||
|↓ | |↓ | ||
|Urinary free cortisone ↓↓ | |||
|dexamethasone and/or MR-blockers | |dexamethasone and/or MR-blockers | ||
|- | |- | ||
Line 171: | Line 169: | ||
|↓ | |↓ | ||
|↓ | |↓ | ||
| | |||
|amiloride or triamterene can reverse the clinical picture reactivating the renin aldosterone | |amiloride or triamterene can reverse the clinical picture reactivating the renin aldosterone | ||
|- | |- | ||
Line 178: | Line 177: | ||
| | | | ||
| | | | ||
|↓ | |||
| | | | ||
| | * ↓ if excess cortisol saturates 11-HSD2 enzyme activity | ||
* ↑ in direct activation of renin angiotensin system activation by glucocorticoids | |||
|Urinary free cortisol markedly ↑↑ | |||
| | | | ||
|- | |- | ||
Line 188: | Line 191: | ||
|↓ | |↓ | ||
|↓ | |↓ | ||
| | |||
|dexamethasone | |dexamethasone | ||
|- | |- | ||
|Aldosterone-secreting adrenocortical carcinoma | |Aldosterone-secreting adrenocortical carcinoma | ||
| | |||
| | | | ||
| | | | ||
Line 204: | Line 209: | ||
|↓ | |↓ | ||
|↓ | |↓ | ||
| | |||
| | | | ||
|- | |- | ||
Line 212: | Line 218: | ||
|↓ | |↓ | ||
|↓ | |↓ | ||
| | |||
|thiazide diuretics and/or dietary sodium restriction | |thiazide diuretics and/or dietary sodium restriction | ||
|- | |- | ||
| rowspan="7" |Exogenous causes | | rowspan="7" |Exogenous causes | ||
|Corticosteroids with mineralocorticoid activity | |Corticosteroids with mineralocorticoid activity | ||
| | |||
| | | | ||
| | | | ||
Line 224: | Line 232: | ||
|- | |- | ||
|Hypersodic diets | |Hypersodic diets | ||
| | |||
| | | | ||
| | | | ||
Line 232: | Line 241: | ||
|- | |- | ||
|Water intossications | |Water intossications | ||
| | |||
| | | | ||
| | | | ||
Line 239: | Line 249: | ||
| | | | ||
|- | |- | ||
|Licorice | |Licorice ingestion | ||
| | | | ||
| | | | ||
| | | | ||
|↓ | |||
|↓ | |||
|Urinary free cortisol Moderate ↑ | |||
| | | | ||
|- | |- | ||
|grapefruit | |grapefruit | ||
| | |||
| | | | ||
| | | | ||
Line 256: | Line 268: | ||
|- | |- | ||
|Contraceptives | |Contraceptives | ||
| | |||
| | | | ||
| | | | ||
Line 264: | Line 277: | ||
|- | |- | ||
|Some progestins | |Some progestins | ||
| | |||
| | | | ||
| | | | ||
Line 273: | Line 287: | ||
| rowspan="7" |Particular causes of hypertension | | rowspan="7" |Particular causes of hypertension | ||
|Sclerosis of juxtaglomerular apparatus (diabetic microangiopathy and/or of the elderly) | |Sclerosis of juxtaglomerular apparatus (diabetic microangiopathy and/or of the elderly) | ||
| | |||
| | | | ||
| | | | ||
Line 281: | Line 296: | ||
|- | |- | ||
|FANS | |FANS | ||
| | |||
| | | | ||
| | | | ||
Line 289: | Line 305: | ||
|- | |- | ||
|B-Adrenergic agonists | |B-Adrenergic agonists | ||
| | |||
| | | | ||
| | | | ||
Line 297: | Line 314: | ||
|- | |- | ||
|Aging | |Aging | ||
| | |||
| | | | ||
| | | | ||
Line 305: | Line 323: | ||
|- | |- | ||
|Low-renin essential hypertension | |Low-renin essential hypertension | ||
| | |||
| | | | ||
| | | | ||
Line 313: | Line 332: | ||
|- | |- | ||
|Autonomic dysfunction | |Autonomic dysfunction | ||
| | |||
| | | | ||
| | | | ||
Line 321: | Line 341: | ||
|- | |- | ||
|Partial/total nephrectomy or removal of renal tissue | |Partial/total nephrectomy or removal of renal tissue | ||
| | |||
| | | | ||
| | | |
Revision as of 18:39, 15 September 2017
Hyperaldosteronism Main page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
This page contains general information about Hyperaldosteronism. For more information on specific types, please visit the pages on Primary hyperaldosteronism, and Secondary hyperaldosteronism.
Synonyms and keywords: Aldosteronism
Overview
Classification
Aldosteronism and mineralocorticoid excess may be classified into two types, primary hyperaldosteronism (conn's syndrome) and secondary hyperaldosteronism. The different types of aldosteronism described in the below table:
High renin causes | Disease | |||
---|---|---|---|---|
Genetic mutation | Bartter and Gitelman syndromes | Hyperplasia of the juxtaglomerular apparatus (the source of renin in the kidney), | ||
Liddle syndrome or pseudohypoaldosteronism type 1 | due to resistance to the actions of aldosterone | |||
Renovascular | Kidney transplant | |||
Renin-secreting juxtaglomerular cell tumors | ||||
Scleroderma renal crisis | ||||
Malignant hypertension | ||||
Tumors | Reninoma | |||
Intravascular hypovolemia | heart failure, hepatic cirrhosis, and nephrotic syndrome |
Classification | Disease | Cause | Laboratory | |||
---|---|---|---|---|---|---|
Renin activity | Aldosterone levels | urinary free cortisone | ||||
Secondary hyperaldosteronism | Renin-producing tumors | ↑ | ↑ | ↓ | ||
Renal artery stenosis | ||||||
Cushing syndrome | ||||||
Ectopic ACTH production | ↓ | ↑ | Markedly ↑↑ | |||
Primary hyperaldosteronism | Primary hyperaldosteronism | ↓ | ↑ | ↓ | ||
Familial hyperaldosteronism | ↓ | ↑ | ↓ |
Pseudohyperaldosteronism causes:
Pseudohyperaldosteronism causes | Disease | Cause | Labratory | |||||
---|---|---|---|---|---|---|---|---|
Elevated mineralocorticoid | Renin | Aldosterone | Other | Treatment | ||||
Endogenous causes | Deficiency of 17a-hydroxylase | Deoxycorticosterone (DOC) | ↓ | ↓ | ||||
11b-hydroxylase | ||||||||
Apparent mineralocorticoid excess syndrome (AME) | Genetic or acquired defect of 11-HSD | ↓ | ↓ | Urinary free cortisone ↓↓ | dexamethasone and/or MR-blockers | |||
Liddle’s syndrome | Mutation of the epithelial sodium channels (ENaC) gene in the distal renal tubules | ↓ | ↓ | amiloride or triamterene can reverse the clinical picture reactivating the renin aldosterone | ||||
Cushing’s syndrome | The main pathogenetic mechanism is linked to the excess
of cortisol which saturates 11-HSD2 activity, allowing cortisol to bind MR. A similar picture is also related to over secretion of cortisol by adrenocortical carcinomas. In some cases the disease is associated with secondary hyperaldosteronism due to a direct activation of the renin angiotensin system by glucocorticoids. |
↓ |
|
Urinary free cortisol markedly ↑↑ | ||||
Insensitivity to glucocorticoids (Chrousos syndrome) | mutations in glucocorticoid receptor (GR) gene | Deoxycorticosterone (DOC) | ↓ | ↓ | dexamethasone | |||
Aldosterone-secreting adrenocortical carcinoma | ||||||||
Geller’s syndrome | mutation of MR that alters its specificity and allows progesterone to bind MR | severe hypertension particularly during pregnancy | ↓ | ↓ | ||||
Gordon’s syndrome or pseudohypoaldosteronism type 2 | due to different mutations correlated to different phenotypes. Mutations of at least four genes have been identified, including WNK1 and WNK4 | hypertension, characterized by hyperkalemia, normal renal function | ↓ | ↓ | thiazide diuretics and/or dietary sodium restriction | |||
Exogenous causes | Corticosteroids with mineralocorticoid activity | |||||||
Hypersodic diets | ||||||||
Water intossications | ||||||||
Licorice ingestion | ↓ | ↓ | Urinary free cortisol Moderate ↑ | |||||
grapefruit | ||||||||
Contraceptives | ||||||||
Some progestins | ||||||||
Particular causes of hypertension | Sclerosis of juxtaglomerular apparatus (diabetic microangiopathy and/or of the elderly) | |||||||
FANS | ||||||||
B-Adrenergic agonists | ||||||||
Aging | ||||||||
Low-renin essential hypertension | ||||||||
Autonomic dysfunction | ||||||||
Partial/total nephrectomy or removal of renal tissue |
Differentiating Diagnosis
Hyperaldosteronism should be differentiated from other diseases causing hypertension and hypokalemia for example:
- Renal artery stenosis
- Cushing's syndrome
- Congenital adrenal hyperplasia (CAH)
- Liddle's syndrome
- Diuretic use
- Licorice ingestion
- Renin-secreting tumors
Hypertension and Hypokalemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plasma renin activity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Normal or High (Plasma Renin/Aldosterone ratio <10 | Suppressed (Plasma Renin/Aldosterone ratio >20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*Renin-secreting tumors *Diuretic use *Renovascular hypertension *Coarctation of aorta *Malignant phase hypertension | Urinary aldosterone | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Elevated | Normal | Low | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conn's syndrome (Primary aldosteronism) | Profound K+ depletion | • 17 alpha hydroxylase deficiency • 11 beta hydroxylase deficiency • Liddle's syndrome • Licorice ingestion • Deoxycortisone producing tumor | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Add Mineralocrticoid antagonist for 8 weeks | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BP response | No BP response | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• Deoxycorticosterone excess( Tumor, 17 alpha hydroxylase and 11 beta hydroxylase deficiency) • Licorice ingestion •Glucocorticoid resistance | Liddle's syndrome) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||